1. Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases
- Author
-
Cardoso, Ana Luisa, Fernandes, Adelaide, Aguilar-Pimentel, Juan Antonio, de Angelis, Martin Hrabě, Guedes, Joana Ribeiro, Brito, Maria Alexandra, Ortolano, Saida, Pani, Giovambattista, Athanasopoulou, Sophia, Gonos, Efstathios S., Schosserer, Marku, Grillari, Johanne, Peterson, Pärt, Tuna, Bilge Guvenc, Dogan, Soner, Meyer, Angelika, van Os, Ronald, Trendelenburg, Anne-Ulrike, Pani, Giovambattista (ORCID:0000-0001-7133-8728), Cardoso, Ana Luisa, Fernandes, Adelaide, Aguilar-Pimentel, Juan Antonio, de Angelis, Martin Hrabě, Guedes, Joana Ribeiro, Brito, Maria Alexandra, Ortolano, Saida, Pani, Giovambattista, Athanasopoulou, Sophia, Gonos, Efstathios S., Schosserer, Marku, Grillari, Johanne, Peterson, Pärt, Tuna, Bilge Guvenc, Dogan, Soner, Meyer, Angelika, van Os, Ronald, Trendelenburg, Anne-Ulrike, and Pani, Giovambattista (ORCID:0000-0001-7133-8728)
- Abstract
Objective: Use of the frailty index to measure an accumulation of deficits has been proven a valuable method for identifying elderly people at risk for increased vulnerability, disease, injury, and mortality. However, complementary molecular frailty biomarkers or ideally biomarker panels have not yet been identified. We conducted a systematic search to identify biomarker candidates for a frailty biomarker panel. Methods: Gene expression databases were searched (http://genomics.senescence.info/genes including GenAge, AnAge, LongevityMap, CellAge, DrugAge, Digital Aging Atlas) to identify genes regulated in aging, longevity, and age-related diseases with a focus on secreted factors or molecules detectable in body fluids as potential frailty biomarkers. Factors broadly expressed, related to several “hallmark of aging” pathways as well as used or predicted as biomarkers in other disease settings, particularly age-related pathologies, were identified. This set of biomarkers was further expanded according to the expertise and experience of the authors. In the next step, biomarkers were assigned to six “hallmark of aging” pathways, namely (1) inflammation, (2) mitochondria and apoptosis, (3) calcium homeostasis, (4) fibrosis, (5) NMJ (neuromuscular junction) and neurons, (6) cytoskeleton and hormones, or (7) other principles and an extensive literature search was performed for each candidate to explore their potential and priority as frailty biomarkers. Results: A total of 44 markers were evaluated in the seven categories listed above, and 19 were awarded a high priority score, 22 identified as medium priority and three were low priority. In each category high and medium priority markers were identified. Conclusion: Biomarker panels for frailty would be of high value and better than single markers. Based on our search we would propose a core panel of frailty biomarkers consisting of (1) CXCL10 (C-X-C motif chemokine ligand 10), IL-6 (interleukin 6), CX3CL1 (C-X3-C motif ch
- Published
- 2018